[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.205.150.215. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Editorial
August 2013

Whither Hope for Pharmacological Treatment of Charcot-Marie-Tooth Disease Type 1A?

Author Affiliations
  • 1Institute for Genetic Medicine, Keck School of Medicine, University of Southern California, Los Angeles
  • 2Institute for Pediatric Regenerative Medicine, University of California–Davis, Sacramento
JAMA Neurol. 2013;70(8):969-971. doi:10.1001/jamaneurol.2013.3285

Charcot-Marie-Tooth disease type 1A (CMT1A) is a dominantly inherited, slowly progressive, often-disabling symmetrical distal sensorimotor polyneuropathy, caused by duplication of 1.5 Mb on the short arm of chromosome 17 with consequent trisomy for PMP22 (peripheral myelin protein 22) encoding a peripheral nervous system myelin protein, that affects about 1 in 2000 people. Other than braces and other orthopedic interventions, no effective treatments of CMT1A are available. A report in 2004 by Passage et al1 found that treating PMP22 transgenic mice with a dose of ascorbic acid (AA; vitamin C) that would be equivalent to administration of 4 g of AA per day to an average adult human diminished peripheral nerve PMP22 mRNA abundance 10-fold. The findings that it also restored the peripheral nerve myelin sheath thickness to normal, improved clinical neurological function, and enhanced life span were greeted with great excitement among neuromuscular physicians.

First Page Preview View Large
First page PDF preview
First page PDF preview
×